RÉSUMÉ
In response to the 2015 Zika virus (ZIKV) epidemic that occurred in Brazil, numerous commercial serological assays have been developed for clinical and research applications. Diagnosis of recent infection in pregnant women remains challenging. Having standardized, comparative studies of ZIKV tests is important for implementing optimal diagnostic testing and disease surveillance. This is especially important for serology tests used to detect ZIKV infection given that antibodies against ZIKV can cross-react with other arboviruses in the same virus family, such as dengue virus (DENV), yellow fever virus (YFV) and West Nile virus (WNV). We looked at the sensitivity and specificity of tests detecting ZIKV antibodies (IgM, IgG) from multiple manufacturers using panels of samples previously collected with known exposure to ZIKV and other arboviruses. We found that performance of the IgM tests was highly variable, with only one test (Inbios 2.0 IgM capture ELISA) having both high sensitivity and specificity. All IgG tests showed good sensitivity; however, specificity was highly variable, with some assays giving false-positive results on samples infected by another flavivirus. Overall, the results confirmed that accurate ZIKV antibody testing is challenging, especially in specimens from regions endemic for multiple other flaviviruses, and highlight the importance of available and suitable reference samples to evaluate ZIKV diagnostics.
Sujet(s)
Anticorps antiviraux , Immunoglobuline G , Immunoglobuline M , Sensibilité et spécificité , Tests sérologiques , Infection par le virus Zika , Virus Zika , Humains , Virus Zika/immunologie , Infection par le virus Zika/diagnostic , Infection par le virus Zika/immunologie , Infection par le virus Zika/sang , Anticorps antiviraux/sang , Anticorps antiviraux/immunologie , Tests sérologiques/méthodes , Tests sérologiques/normes , Immunoglobuline M/sang , Immunoglobuline G/sang , Test ELISA/méthodes , Test ELISA/normes , Réactions croisées/immunologie , Femelle , Grossesse , BrésilRÉSUMÉ
Recently, respiratory syncytial virus (RSV) vaccines based on the prefusion F (pre-F) antigen were approved in the United States. We aimed to develop an enzyme-linked immunosorbent assay (ELISA)-based protocol for the practical and large-scale evaluation of RSV vaccines. Two modified pre-F proteins (DS-Cav1 and SC-TM) were produced by genetic recombination and replication using an adenoviral vector. The protocol was established by optimizing the concentrations of the coating antigen (pre-F proteins), secondary antibodies, and blocking buffer. To validate the protocol, we examined its accuracy, precision, and specificity using serum samples from 150 participants across various age groups and the standard serum provided by the National Institute of Health. In the linear correlation analysis, coating concentrations of 5 and 2.5 µg/mL of DS-Cav1 and SC-TM showed high coefficients of determination (r > 0.90), respectively. Concentrations of secondary antibodies (alkaline phosphatase-conjugated anti-human immunoglobulin G, diluted 1:2000) and blocking reagents (5% skim milk/PBS-T) were optimized to minimize non-specific reactions. High accuracy was observed for DS-Cav1 (r = 0.90) and SC-TM (r = 0.86). Further, both antigens showed high precision (coefficient of variation < 15%). Inhibition ELISA revealed cross-reactivity of antibodies against DS-Cav1 and SC-TM, but not with the attachment (G) protein.
Sujet(s)
Anticorps antiviraux , Test ELISA , Infections à virus respiratoire syncytial , Vaccins contre les virus respiratoires syncytiaux , Virus respiratoire syncytial humain , Test ELISA/méthodes , Test ELISA/normes , Humains , Infections à virus respiratoire syncytial/prévention et contrôle , Infections à virus respiratoire syncytial/immunologie , Infections à virus respiratoire syncytial/diagnostic , Anticorps antiviraux/sang , Anticorps antiviraux/immunologie , Vaccins contre les virus respiratoires syncytiaux/immunologie , Virus respiratoire syncytial humain/immunologie , Nourrisson , Enfant d'âge préscolaire , Adulte , Enfant , Adolescent , Adulte d'âge moyen , Jeune adulte , Femelle , Sensibilité et spécificité , Antigènes viraux/immunologie , Mâle , Protéines de fusion virale/immunologie , Sujet âgéRÉSUMÉ
The continuing mutability of the SARS-CoV-2 virus can result in failures of diagnostic assays. To address this, we describe a generalizable bioinformatics-to-biology pipeline developed for the calibration and quality assurance of inactivated SARS-CoV-2 variant panels provided to Radical Acceleration of Diagnostics programs (RADx)-radical program awardees. A heuristic genetic analysis based on variant-defining mutations demonstrated the lowest genetic variance in the Nucleocapsid protein (Np)-C-terminal domain (CTD) across all SARS-CoV-2 variants. We then employed the Shannon entropy method on (Np) sequences collected from the major variants, verifying the CTD with lower entropy (less prone to mutations) than other Np regions. Polyclonal and monoclonal antibodies were raised against this target CTD antigen and used to develop an Enzyme-linked immunoassay (ELISA) test for SARS-CoV-2. Blinded Viral Quality Assurance (VQA) panels comprised of UV-inactivated SARS-CoV-2 variants (XBB.1.5, BF.7, BA.1, B.1.617.2, and WA1) and distractor respiratory viruses (CoV 229E, CoV OC43, RSV A2, RSV B, IAV H1N1, and IBV) were assembled by the RADx-rad Diagnostics core and tested using the ELISA described here. The assay tested positive for all variants with high sensitivity (limit of detection: 1.72-8.78 ng/mL) and negative for the distractor virus panel. Epitope mapping for the monoclonal antibodies identified a 20 amino acid antigenic peptide on the Np-CTD that an in-silico program also predicted for the highest antigenicity. This work provides a template for a bioinformatics pipeline to select genetic regions with a low propensity for mutation (low Shannon entropy) to develop robust 'pan-variant' antigen-based assays for viruses prone to high mutational rates.
Sujet(s)
Antigènes viraux , COVID-19 , Protéines de la nucléocapside des coronavirus , Phosphoprotéines , SARS-CoV-2 , SARS-CoV-2/immunologie , SARS-CoV-2/génétique , Humains , Protéines de la nucléocapside des coronavirus/immunologie , Protéines de la nucléocapside des coronavirus/génétique , COVID-19/diagnostic , COVID-19/immunologie , COVID-19/virologie , Antigènes viraux/immunologie , Antigènes viraux/génétique , Phosphoprotéines/immunologie , Phosphoprotéines/génétique , Test ELISA/méthodes , Test ELISA/normes , Dépistage sérologique de la COVID-19/méthodes , Dépistage sérologique de la COVID-19/normes , Anticorps antiviraux/immunologie , Anticorps monoclonaux/immunologie , Biologie informatique/méthodes , Mutation , AnimauxRÉSUMÉ
BACKGROUND: Improving harmonization of the clinical interpretation of anticardiolipin (aCL) and anti-ß2-glycoprotein I (aß2GPI) antibodies immunoglobulin G (IgG)/immunoglobulin M (IgM) in the diagnosis of antiphospholipid syndrome (APS) is desirable. Likelihood ratios (LRs) with corresponding test-result intervals can identify the power of a test to discriminate between a diseased and nondiseased patient and may be useful for the semiquantitative interpretation of aCL/aß2GPI results. OBJECTIVES: To determine moderate and high thresholds for aCL and aß2GPI IgG/IgM measured with chemiluminescent immunoassay, enzyme-linked immunosorbent assay, fluorescence enzyme immunoassay, and multiplex flow immunoassay. METHODS: aCL and aß2GPI antibodies IgG/IgM were determined with 4 solid-phase systems in a case-control study population including 381 APS patients and 727 controls. Interval-specific LRs (IS-LR) were calculated for ranges determined by prespecified specificity and sensitivity levels. Three methods were used for determining thresholds that separated low, moderate, and high positive antibody levels. Interassay agreement was checked with Cohen's kappa statistics. RESULTS: Assay- and antibody-specific thresholds demonstrated increasing IS-LR, reflecting different clinical significance for low, moderate, and high levels, especially for IgG aCL and aß2GPI and in thrombotic APS. IS-LRs per antibody and unit range were comparable across solid-phase platforms resulting in enhanced harmonization of result interpretation. Agreement between assays for identifying high levels was improved by semiquantitative interpretation compared with that by quantitative reporting. CONCLUSION: aCL and aß2GPI IgG/IgM moderate and high thresholds were determined for 4 analytical platforms. Thresholds improve harmonized interpretation of aCL/aß2GPI levels across platforms. The proposed thresholds should be verified in an independent case-control study to check interlaboratory transferability.
Sujet(s)
Anticorps anticardiolipines , Syndrome des anticorps antiphospholipides , Immunoglobuline G , Inhibiteur lupique de la coagulation , bêta 2-Glycoprotéine I , Syndrome des anticorps antiphospholipides/diagnostic , Syndrome des anticorps antiphospholipides/sang , Syndrome des anticorps antiphospholipides/immunologie , Humains , Anticorps anticardiolipines/sang , bêta 2-Glycoprotéine I/immunologie , Inhibiteur lupique de la coagulation/sang , Études cas-témoins , Immunoglobuline G/sang , Femelle , Mâle , Anticorps antiphospholipides/sang , Fonctions de vraisemblance , Immunoglobuline M/sang , Valeur prédictive des tests , Test ELISA/normes , Test ELISA/méthodes , Adulte d'âge moyen , Adulte , Reproductibilité des résultats , Marqueurs biologiques/sang , Mesures de luminescenceRÉSUMÉ
BACKGROUND: Manufacturers and diagnostic companies often recommend on-site verification of analytical performance in the clinical laboratory. The validation process used by manufacturers is rarely described in detail, and certain information on analytical performance is missing from the product sheet, especially for immunoanalytical methods. We describe an approach to the detailed validation of an ELISA method for the measurement of proprotein convertase subtilisin/kexin type 9 (PCSK9) plasma concentrations. We compared manufacturers' claims of analytical performance with data obtained in the field laboratory using several approaches. METHODS: We used the Human Proprotein Convertase 9/PCSK9 Quantikine ELISA diagnostic kit (R&D systems, Bio-Techne Ltd., Abingdon Science Park, Abingdon, UK) and three levels of quality control solution Quantikine Immunoassay Control Group 235 (R&D systems, Bio-Techne Ltd., Abingdon Science Park, Abingdon, UK) to verify precision. We measured the concentration of PCSK9 using the DS2 ELISA Reader (Dynex Technologies GmbH, Denkendorf, Germany). We used analysis of variance (ANOVA) and the R statistical package (R core team, version 1.4.5). Statistical analysis and terminology were performed according to protocol CLSI EP15-A3, and the reference interval was checked according to CLSI/IFCC C28-A3c. RESULTS: We found a significant difference between the manufacturer's claims of analytical performance and real data measured in the routine clinical laboratory. The calculated CV (%) for repeatability (calculated by simple estimation of the mean and SD, as used by the manufacturer) was between 5.5% and 7.4%, but the manufacturer's claim was between 4.1% and 6.5%. Using ANOVA, the true repeatability was between 5.0% and 6.9%. Similarly, ANOVA revealed values of CV (%) for within-laboratory imprecision between 6.5% and 9.1%, while the manufacturer's claims were between 4.1% and 5.9%. The recovery ranged from 105.5% to 121.8%. The manufacturer's recommended reference interval was checked and we didn't find any significant difference between men and women. CONCLUSIONS: We describe a comprehensive approach to verify the analytical performance of an ELISA method using the measurement of PCSK9 plasma concentration as an example. We found differences between the results of this approach based on the CLSI EP15-A3 protocol and data provided by the manufacturer. We recommend the verification of analytical performance by more complex statistical tools in laboratory practice.
Sujet(s)
Test ELISA , Proprotéine convertase 9 , Humains , Proprotéine convertase 9/sang , Proprotéine convertase 9/immunologie , Test ELISA/normes , Test ELISA/méthodes , Reproductibilité des résultats , Femelle , Mâle , Trousses de réactifs pour diagnostic/normes , Contrôle de qualitéRÉSUMÉ
The interpretation for Zika virus serology results is challenging due to high antibody cross reactivity with other flaviviruses. This limits availability of reliable and accurate methods for serosurveillance studies to understand the disease burden. Therefore, we conducted study to harmonize anti-Zika IgG antibody detection assays with 1st WHO International Standard (16/352) and working standard (16/320) for anti-Zika virus antibody.Additionally, evaluated NuGenTMZIKA-IgG and NovaLisa®ZIKA virus IgG-Capture ELISA using a panel of 278 seraFurther, 106 samples positive for other-flavi viruses were taken for assessing cross-reactivity of the assay, all serums were further tested by Zika-PRNT. The results of this study indicates satisfactory performance of both the assays. Serological and neutralization assays were calibrated according to the international standards. This will help in understanding antibody dynamics in serosurveillance and vaccine studies. However the performance of the kits with possibilities of cross-reactivity will have to be verified by coupling ZIKV and DENV specific ELISA.
Sujet(s)
Anticorps antiviraux , Réactions croisées , Test ELISA , Immunoglobuline G , Infection par le virus Zika , Virus Zika , Test ELISA/méthodes , Test ELISA/normes , Virus Zika/immunologie , Immunoglobuline G/sang , Humains , Anticorps antiviraux/sang , Infection par le virus Zika/diagnostic , Infection par le virus Zika/immunologie , Infection par le virus Zika/sang , Trousses de réactifs pour diagnostic/normes , Tests sérologiques/normes , Tests sérologiques/méthodes , Sensibilité et spécificité , Femelle , Adulte , Adolescent , Jeune adulteRÉSUMÉ
BACKGROUND: Several laboratory techniques for anti double-stranded (ds) DNA detection in systemic lupus erythematosus (SLE) are available, with variable diagnostic performance. We aimed to evaluate anti-dsDNA's diagnostic performance by indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assay (EIA). METHODS: We conducted a single-center retrospective (2015 to 2020) study. Patients with anti-dsDNA tests by IIF and EIA were included. We evaluated the indications, applications, concordance, positive predictive value (PPV) of anti-dsDNA to confirm SLE diagnosis or flares, and associations of disease manifestations with positivity with each technique. RESULTS: A total of 1368 reports of anti-dsDNA tests by IIF and EIA and the corresponding medical records of the patients were analyzed. The main indication for anti-dsDNA testing was to help in the diagnosis of SLE in 890 (65%) of the samples, and the main application after obtaining the results was SLE exclusion in 782 (57.2%) cases. The combination with the highest frequency was the negativity result by both techniques in 801 (58.5%) cases (Cohen kappa 0.57). Both methods were positive in 300 patients with SLE (Cohen kappa 0.42). The PPVs of anti-dsDNA tests to confirm diagnosis/flare was 79.64% (95% CI, 75.35-83.35) by EIA, 78.75% (95% CI, 74.27-82.62) by IIF, and 82% (95% CI, 77.26-85.93) when both were positive. CONCLUSIONS: Anti-dsDNA detection by IIF and EIA are complementary and may indicate different clinical patterns in patients with SLE. The detection of anti-dsDNA antibodies by both techniques has a higher PPV than either separately for confirming SLE diagnosis or flares. These results highlight the need for evaluating both methods in clinical practice.
Sujet(s)
Anticorps antinucléaires , Lupus érythémateux disséminé , Humains , Test ELISA/normes , Technique d'immunofluorescence indirecte/normes , Lupus érythémateux disséminé/diagnostic , Études rétrospectives , Anticorps antinucléaires/analyse , Mâle , Femelle , Jeune adulte , Adulte , Adulte d'âge moyen , Valeur prédictive des tests , Analyse de régressionRÉSUMÉ
Oral fluids offer a noninvasive sampling method for the detection of Abs. Quantification of IgA and IgG Abs in saliva allows studies of the mucosal and systemic immune response after natural infection or vaccination. We developed and validated an enzyme immunoassay (EIA) to detect and quantify salivary IgA and IgG Abs against the prefusion-stabilized form of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein expressed in suspension-adapted HEK-293 cells. Normalization against total Ab isotype was performed to account for specimen differences, such as collection time and sample volume. Saliva samples collected from 187 SARS-CoV-2 confirmed cases enrolled in 2 cohorts and 373 prepandemic saliva samples were tested. The sensitivity of both EIAs was high (IgA, 95.5%; IgG, 89.7%) without compromising specificity (IgA, 99%; IgG, 97%). No cross-reactivity with endemic coronaviruses was observed. The limit of detection for SARS-CoV-2 salivary IgA and IgG assays were 1.98 ng/ml and 0.30 ng/ml, respectively. Salivary IgA and IgG Abs were detected earlier in patients with mild COVID-19 symptoms than in severe cases. However, severe cases showed higher salivary Ab titers than those with a mild infection. Salivary IgA titers quickly decreased after 6 wk in mild cases but remained detectable until at least week 10 in severe cases. Salivary IgG titers remained high for all patients, regardless of disease severity. In conclusion, EIAs for both IgA and IgG had high specificity and sensitivity for the confirmation of current or recent SARS-CoV-2 infections and evaluation of the IgA and IgG immune response.
Sujet(s)
Anticorps antiviraux/métabolisme , COVID-19/diagnostic , Test ELISA/méthodes , Immunoglobuline A/métabolisme , Immunoglobuline G/métabolisme , SARS-CoV-2/physiologie , Salive/métabolisme , Adolescent , Adulte , Sujet âgé , Maladies asymptomatiques , Enfant , Enfant d'âge préscolaire , Évolution de la maladie , Test ELISA/normes , Femelle , Humains , Nourrisson , Mâle , Dépistage de masse , Adulte d'âge moyen , Pandémies , Normes de référence , Sensibilité et spécificité , Indice de gravité de la maladie , Jeune adulteSujet(s)
Antibactériens/usage thérapeutique , Notification des maladies/normes , Prescription inappropriée/statistiques et données numériques , Maladie de Lyme/diagnostic , Types de pratiques des médecins/statistiques et données numériques , Adulte , Test ELISA/méthodes , Test ELISA/normes , Femelle , Humains , Maladie de Lyme/traitement médicamenteux , Mâle , Massachusetts/épidémiologie , Adulte d'âge moyen , Surveillance de la population , Amélioration de la qualité , Jeune adulteRÉSUMÉ
This research has developed a method for rapid detection of SARS-CoV-2 N protein on a paper-based microfluidic chip. The chitosan-glutaraldehyde cross-linking method is used to fix the coated antibody, and the sandwich enzyme-linked immunosorbent method is used to achieve the specific detection of the target antigen. The system studied the influence of coating antibody concentration and enzyme-labeled antibody concentration on target antigen detection. According to the average gray value measured under different N protein concentrations, the standard curve of the method was established and the sensitivity was tested, and its linear regression was obtained. The equation is y = 9.8286x+137.6, R2 = 0.9772 > 0.90, which shows a high degree of fit. When the concentration of coating antibody and enzyme-labeled antibody were 1 µg/mL and 2 µg/mL, P > 0.05, the difference was not statistically significant, so the lower concentration of 1 µg/mL was chosen as the coating antibody concentration. The results show that the minimum concentration of N protein that can be detected by this method is 8 µg/mL, and the minimum concentration of coating antibody and enzyme-labeled antibody is 1 µg/mL, which has the characteristics of high sensitivity and good repeatability.
Sujet(s)
Antigènes viraux/analyse , Dépistage sérologique de la COVID-19/instrumentation , Protéines de la nucléocapside des coronavirus/analyse , Protéines de la nucléocapside des coronavirus/immunologie , Laboratoires sur puces , SARS-CoV-2/composition chimique , SARS-CoV-2/immunologie , Anticorps antiviraux/immunologie , Génie biomédical , COVID-19/diagnostic , COVID-19/immunologie , COVID-19/virologie , Dépistage sérologique de la COVID-19/méthodes , Dépistage sérologique de la COVID-19/normes , Protéines de la nucléocapside des coronavirus/normes , Test ELISA/instrumentation , Test ELISA/méthodes , Test ELISA/normes , Humains , Laboratoires sur puces/normes , Laboratoires sur puces/statistiques et données numériques , Procédures d'analyse sur micropuce/méthodes , Procédures d'analyse sur micropuce/normes , Procédures d'analyse sur micropuce/statistiques et données numériques , Papier , Phosphoprotéines/analyse , Phosphoprotéines/immunologie , Phosphoprotéines/normesRÉSUMÉ
Dengue, caused by the dengue virus (DENV) is a significant vector-borne disease. In absence of a specific treatment and vaccine, dengue is becoming a rising threat to public health. Currently, control of dengue mainly focuses on the surveillance of the mosquito vectors. Improved surveillance methods for DENV in mosquito populations would be highly beneficial to the public health. However, current methods of DENV detection in mosquitoes requires specialized equipment and expensive reagents and highly trained personnel. As an alternative, commercially available dengue NS1 antigen ELISA kits could be used for detection of DENV infection in Aedes aegypti mosquitoes. In this study, we explored the utility of commercially available Dengue NS1 antigen kit (J. Mitra & Co. Pvt. Ltd) for the detection of recombinant dengue virus-2 (rDENV-2) NS1 protein and serum of dengue infected patient spiked with Ae. aegypti mosquito pools. The kit was found to be highly sensitive and specific towards detection of all serotypes of DENV. Further, it could detect as low as 750 femto gram rDENV-2 NS1 protein. It was also observed that rDENV-2 NS1 antigen spiked with blood-fed and unfed mosquito pools could be detected. In addition, the kit also detected dengue infected patient serum spiked with Ae. aegypti mosquito pools. Overall, the Dengue NS1 antigen kit displayed high sensitivity towards detection of recombinant as well as serum NS1 protein spiked with Ae. aegypti mosquito pools and could be considered for the dengue virus surveillance after a field evaluation in Ae. aegypti mosquitoes.
Sujet(s)
Aedes/virologie , Antigènes viraux/immunologie , Virus de la dengue/immunologie , Test ELISA/méthodes , Vecteurs moustiques/virologie , Protéines virales non structurales/immunologie , Aedes/immunologie , Animaux , Dengue/diagnostic , Dengue/immunologie , Dengue/transmission , Dengue/virologie , Virus de la dengue/classification , Test ELISA/normes , Humains , Vecteurs moustiques/immunologie , Trousses de réactifs pour diagnostic , Sensibilité et spécificité , SérogroupeRÉSUMÉ
Human immunodeficiency virus-1 (HIV-1) persistence in the presence of antiretroviral therapy (ART) has halted the development of curative strategies. Measuring HIV persistence is complex due to the low frequency of cells containing virus in vivo. Most of the commercially available assays to date measure nucleic acid. These assays have the advantage of being highly sensitive and allow for the analysis of sequence diversity, intactness of the HIV genome or evaluation of diverse RNA species. However, these assays are limited in evaluating translational competent viral reservoirs. In here, we developed an ultrasensitive p24 ELISA that uses the Simoa planar array technology that can detect HIV-1 virions and HIV-1 infected cell with limit of detection similar to nucleic acid assays. Furthermore, the assay is optimized to measure very low levels of p24 in different biological fluids without a major loss of sensitivity or reproducibility. Our results demonstrate that the 'homebrew' planar p24 ELISA immunoassay is a broadly applicable new tool to evaluate HIV persistence in diverse biological fluids and cells.
Sujet(s)
Test ELISA , Protéine de capside p24 du VIH/métabolisme , Infections à VIH/diagnostic , Infections à VIH/virologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/métabolisme , Test ELISA/méthodes , Test ELISA/normes , Protéine de capside p24 du VIH/immunologie , Humains , Reproductibilité des résultats , Sensibilité et spécificitéRÉSUMÉ
Early detection of any preeclampsia biomarkers may lower the risk of mortality, both for a mother and a child. Our study focuses on techniques for preeclampsia biomarker identification by comparing the results of a method using liquid chromatography mass spectrometry in multiple reaction monitoring mode (LC-MS/MS) with those by the enzyme-linked immunosorbent assay (ELISA) test, as well as by comparing the obtained results with clinical data. In the proposed LC-MS/MS method a tryptic digest peptide charge derivatization strategy was used as a tool for sensitive detection of podocin, i.e., a previously discovered preeclampsia biomarker present in urine samples from pregnant women. Urine samples from pregnant women with diagnosed preeclampsia were collected at different stages of pregnancy and from healthy subjects, and then were analyzed by ELISA test and the proposed method with LC-MS/MS. Charge derivatization of the ε amino group of C-terminal lysine residues in tryptic digests by 2,4,6-triphenylpyrylium salt was performed to increase the ionization efficiency in the LC-MS/MS mode. Podocin was identified at the early stage of pregnancy, while its detection using an ELISA test was not possible. The protocol for urine sample preparation was optimized. Our results show that the proposed method by LC-MS/MS in combination with peptide charge derivatization, provides an ultrasensitive tool for diagnosis of preeclampsia, and provides earlier detection than a clinical diagnosis or ELISA test. The proposed solution may revolutionize medical diagnostics.
Sujet(s)
Marqueurs biologiques/composition chimique , Diagnostic précoce , Peptides/composition chimique , Pré-éclampsie/diagnostic , Adulte , Chromatographie en phase liquide à haute performance , Test ELISA/normes , Femelle , Humains , Spectrométrie de masse , Peptides/isolement et purification , Pré-éclampsie/métabolisme , Pré-éclampsie/anatomopathologie , Grossesse , Spectrométrie de masse en tandemRÉSUMÉ
Point-of-care (POC) tests to detect SARS-CoV-2 antibodies offer quick assessment of serostatus after natural infection or vaccination. We compared the field performance of the BioMedomics COVID-19 IgM/IgG Rapid Antibody Test against an ELISA in 303 participants enrolled in a SARS-CoV-2 household cohort study. The rapid antibody test was easily implemented with consistent interpretation across 14 users in a variety of field settings. Compared with ELISA, detection of seroconversion lagged by 5 to 10 days. However, it retained a sensitivity of 90% (160/177, 95% confidence interval [CI] 85-94%) and specificity of 100% (43/43, 95% CI 92-100%) for those tested 3 to 5 weeks after symptom onset. Sensitivity was diminished among those with asymptomatic infection (74% [14/19], 95% CI 49-91%) and early in infection (45% [29/64], 95% CI 33-58%). When used appropriately, rapid antibody tests offer a convenient way to detect symptomatic infections during convalescence.
Sujet(s)
Anticorps antiviraux/sang , COVID-19/diagnostic , Test ELISA , Analyse sur le lieu d'intervention , SARS-CoV-2/immunologie , COVID-19/immunologie , Études de cohortes , Test ELISA/normes , Caractéristiques familiales , Humains , Analyse sur le lieu d'intervention/normes , SARS-CoV-2/isolement et purificationRÉSUMÉ
In the present study, we developed a genus-specific rGroEL1-524 IgM-ELISA assay for use in screening diagnosis of suspected leptospirosis among acute undifferentiated febrile illness patients during acute fever. The diagnostic accuracies of the rGroEL1-524 IgM-ELISA, commercial Panbio IgM-ELISA, and Virion-Serion Classic IgG-ELISA were evaluated using 133 Thai leptospirosis sera and 210 controls. Sensitivities were 91.7%, 59.6%, and 17.7% for acute infection, and the specificities were 92.6%, 90.2%, and 88.3% for the non-leptospirosis control, respectively. The rGroEL1-524 IgM-ELISA had high sensitivity, at 92.3% and 91.7%, among culture-positive and MAT-negative cases at 1-3 days post-onset of symptoms (DPO1-3), respectively. Impaired specificity on scrub typhus was found, possibly from antibody cross-reaction to ortholog GroEL. Commercial Panbio IgM-ELISA had sensitivities at DPO1-3 of 30.8% and 41.7% for culture-positive and MAT-negative cases whereas Virion-Serion IgG-ELISA showed sensitivities of 5.9% and 13.3%, respectively. The rGroEL1-524 IgM-ELISA could be useful as a screening test for early diagnosis. The performance of the commercial ELISA suggests the applicability of IgM-ELISA for diagnosis, while IgG-ELISA is useful for seroprevalence surveys. However, confirmation by reference tests is recommended.
Sujet(s)
Chaperonine-60/immunologie , Test ELISA/méthodes , Test ELISA/normes , Immunoglobuline M/immunologie , Leptospirose/diagnostic , Leptospirose/épidémiologie , Trousses de réactifs pour diagnostic , Anticorps antibactériens/immunologie , Épitopes/immunologie , Humains , Leptospira/immunologie , Dépistage de masse , Sensibilité et spécificité , Études séroépidémiologiques , Thaïlande/épidémiologieRÉSUMÉ
Serological testing is a powerful tool in epidemiological studies for understanding viral circulation and assessing the effectiveness of virus control measures, as is the case of SARS-CoV-2, the pathogenic agent of COVID-19. Immunoassays can quantitatively reveal the concentration of antiviral antibodies. The assessment of antiviral antibody titers may provide information on virus exposure, and changes in IgG levels are also indicative of a reduction in viral circulation. In this work, we describe a serological study for the evaluation of antiviral IgG and IgM antibodies and their correlation with antiviral activity. The serological assay for IgG detection used two SARS-CoV-2 proteins as antigens, the nucleocapsid N protein and the 3CL protease. Cross-reactivity tests in animals have shown high selectivity for detection of antiviral antibodies, using both the N and 3CL antigens. Using samples of human serum from individuals previously diagnosed by PCR for COVID-19, we observed high sensitivity of the ELISA assay. Serological results with human samples also suggest that the combination of higher titers of antiviral IgG antibodies to different antigen targets may be associated with greater neutralization activity, which can be enhanced in the presence of antiviral IgM antibodies.
Sujet(s)
Anticorps antiviraux/immunologie , Dépistage sérologique de la COVID-19/méthodes , COVID-19/diagnostic , COVID-19/prévention et contrôle , Surveillance immunologique , SARS-CoV-2/immunologie , Animaux , Anticorps antiviraux/sang , Antigènes viraux/immunologie , COVID-19/épidémiologie , COVID-19/immunologie , Dépistage sérologique de la COVID-19/normes , Réactions croisées , Virus de la dengue/immunologie , Test ELISA/méthodes , Test ELISA/normes , Femelle , Humains , Immunoglobuline G/sang , Immunoglobuline M/sang , Souris , Souris de lignée BALB C , Sensibilité et spécificité , Virus Zika/immunologieRÉSUMÉ
The diagnosis and monitoring of cancer have been facilitated by discovering tumor "biomarkers" and methods to detect their presence. Yet, for certain cancers, we still lack sensitive and specific biomarkers or the means to quantify subtle concentration changes successfully. The identification of new biomarkers of disease and improving the sensitivity of detection will remain key to changing clinical outcomes. Patient liquid biopsies (serum and plasma) are the most easily obtained sources for noninvasive analysis of proteins that tumor cells release directly and via extracellular microvesicles and tumor shedding. Therefore, an emphasis on creating reliable assays using serum/plasma and "direct, in-solution" ELISA approaches has built an industry centered on patient protein biomarker analysis. A need for improved dynamic range and automation has resulted in the application of ELISA principles to paramagnetic beads with chemiluminescent or fluorescent detection. In the clinical testing lab, chemiluminescent paramagnetic assays are run on automated machines that test a single analyte, minimize technical variation, and are not limited by serum sample volumes. This differs slightly from the R&D setting, where serum samples are often limiting; therefore, multiplexing antibodies to test multiple biomarkers in low serum volumes may be preferred. This review summarizes the development of historical biomarker "standards", paramagnetic particle assay principles, chemiluminescent or fluorescent biomarker detection advancements, and multiplexing for sensitive detection of novel serum biomarkers.
Sujet(s)
Marqueurs biologiques tumoraux , Biopsie liquide/méthodes , Biopsie liquide/normes , Tumeurs/diagnostic , Tumeurs/étiologie , Automatisation , Marqueurs biologiques tumoraux/sang , Colorimétrie/méthodes , Colorimétrie/normes , Prise en charge de la maladie , Test ELISA/méthodes , Test ELISA/normes , Humains , Mesures de luminescence/méthodes , Mesures de luminescence/normes , Tumeurs/sang , Courbe ROC , Sensibilité et spécificitéRÉSUMÉ
BACKGROUND: In characterizing malaria epidemiology, measuring mosquito infectiousness informs the entomological inoculation rate, an important metric of malaria transmission. PCR-based methods have been touted as more sensitive than the current "gold-standard" circumsporozoite (CSP) ELISA. Wider application of PCR-based methods has been limited by lack of specificity for the infectious sporozoite stage. We compared a PCR method for detecting the parasite's mitochondrial (mt) cytochrome oxidase I (COX-I) gene with ELISA for detecting circumsporozoite protein for identification of different life stages of the parasite during development within a mosquito. METHODS: A PCR-based method targeting the Plasmodium mt COX-I gene was compared with the CSP ELISA method to assess infectivity in Anopheles arabiensis colony mosquitoes fed on blood from patients infected with Plasmodium vivax. Mosquitoes were tested at six post-infection time points (days 0.5, 1, 6, 9, 12, 15). The head and thorax and the abdomen for each specimen were tested separately with each method. Agreement between methods at each infection stage was measured using Cohen's kappa measure of test association. RESULTS: Infection status of mosquitoes was assessed in approximately 90 head/thorax and 90 abdomen segments at each time point; in total, 538 head/thorax and 534 abdomen segments were tested. In mosquitoes bisected after 0.5, 1, and 6 days post-infection (dpi), the mt COX-I PCR detected Plasmodium DNA in both the abdomen (88, 78, and 67%, respectively) and head/thorax segments (69, 60, and 44%, respectively), whilst CSP ELISA detected sporozoites in only one abdomen on day 6 post-infection. PCR was also more sensitive than ELISA for detection of Plasmodium in mosquitoes bisected after 9, 12, and 15 dpi in both the head and thorax and abdomen. There was fair agreement between methods for time points 9-15 dpi (κ = 0.312, 95% CI: 0.230-0.394). CONCLUSIONS: The mt COX-I PCR is a highly sensitive, robust method for detecting Plasmodium DNA in mosquitoes, but its limited Plasmodium life-stage specificity cannot be overcome by bisection of the head and thorax from the abdomen prior to PCR. Thus, the mt COX-I PCR is a poor candidate for identifying infectious mosquitoes.
Sujet(s)
Anopheles/parasitologie , Test ELISA/normes , Étapes du cycle de vie/génétique , Plasmodium vivax/génétique , Réaction de polymérisation en chaîne/normes , Sporozoïtes/génétique , Animaux , Test ELISA/méthodes , Femelle , Plasmodium vivax/immunologie , Réaction de polymérisation en chaîne/méthodes , Sporozoïtes/immunologieRÉSUMÉ
Avian mycoplasmosis, mainly caused by Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS) is an economically important disease of the poultry industry. The present study was aimed to develop whole cell based indirect-ELISA (i-ELISA) and DOT blot assay (DOT-ELISA) as rapid, sensitive, specific and economical sero-detection tests for MG and MS. A total of 306 blood samples were collected from birds slaughtered at local meat shops of different districts of Haryana, India to detect MG and MS antibodies. Sonicated antigens prepared from freshly grown culture of MG and MS were used to develop i-ELISA and DOT blot assay. In i-ELISA, 50.32% and 61.76% serum samples were found to be positive for MG and MS antibodies, respectively. However in DOT blot assay, 41.83% and 53.92% serum samples were found positive for MG and MS antibodies, respectively. The relative diagnostic sensitivity and specificity of DOT-ELISA were measured considering i-ELISA as a reference test. The relative diagnostic sensitivity of the DOT blot assay was found to be 69.48% and 82.01%; whereas relative diagnostic specificity was 86.18% and 91.45% for the detection of MG and MS antibodies, respectively. The developed serological assays may be used as rapid and economical diagnostic tools for large scale screening of poultry sera for MG and MS antibodies.
Sujet(s)
Anticorps antibactériens/sang , Test ELISA/normes , Infections à Mycoplasma/diagnostic , Infections à Mycoplasma/médecine vétérinaire , Mycoplasma gallisepticum/immunologie , Mycoplasma synoviae/immunologie , Maladies de la volaille/diagnostic , Animaux , Poulets/immunologie , Poulets/microbiologie , Test ELISA/méthodes , Immunotransfert/méthodes , Inde , Volaille/immunologie , Volaille/microbiologie , Maladies de la volaille/microbiologie , Sensibilité et spécificitéRÉSUMÉ
BACKGROUND: An N-terminal octapeptide cleavage of the cystatin C protein was discovered by mass spectrometry when cerebrospinal fluid (CSF) was stored at -20°C for 3 months, which did not occur when CSF was stored at -80°C. OBJECTIVE: The aim was to develop an immunoassay as quality assessment tool to detect this -20°C cleavage of cystatin C in CSF and support Alzheimer's disease research. METHODS: A specific monoclonal antibody and a double indirect sandwich ELISA were developed: one assay quantifies the octapeptide uncleaved protein specifically and the other quantifies the total cystatin C present in the biological fluid (both cleaved and uncleaved forms). The ratio of these concentrations was calculated to assess the extent of cleavage of cystatin C. The novel ELISA was validated and applied in a short-term (up to 4 weeks) and mid-term (up to one year) stability study of CSF stored at 4°C, -20°C, -80°C, and liquid nitrogen. Impact of freeze-thaw cycles, adsorption, and protease inhibitors were tested. RESULTS: The ratio of truncated protein was modified following -20°C storage and seemed to reach a plateau after 6 months. The ratio was impacted neither by freeze-thaw cycles nor adsorption. The -20°C specific cleavage was found to be protease related. CONCLUSION: Using this novel double indirect sandwich ELISA, absolute levels of the total and uncleaved cystatin C and the ratio of truncated cystatin C can be measured. This assay is an easily applicable tool which can be used to confirm that CSF biospecimen are fit-for-purpose for Alzheimer's disease research.